Sinovac Biotech Ltd., a vaccine-centered biopharmaceutical company headquartered in Beijing, said on Sunday that preliminary trial results show that the COVID-19 inactivated vaccine developed by the company is safe and has good immunogenicity.
According to the company, the vaccine hasn’t caused severe side effects and more than 90% of people administered with the shot on a 14-day interval have induced neutralizing antibodies two weeks after inoculation.
The preliminary findings come from phase I and II trials in eastern China’s Jiangsu province. A total of 743 healthy people aged 18-59 either received shots on two schedules or a placebo.
More data are expected from another group in the trial that received shots on a 28-day interval, the company said.
The adverse reactions after the first and second phases of the 14-day interim presented mostly as mild pain at the injection site, while only a few individuals suffered from low fever or fatigue. No volunteers reported experiencing severe symptoms.
Sinovac started developing a vaccine against the highly infectious novel coronavirus on Jan. 28, and its inactivated vaccine was approved for clinical trials on April 13.
The company plans to submit the phase II clinical study report and phase III plan to the National Medical Products Administration in the near future in the hope that the vaccine can be applied soon after the phase III trial is completed.